TeamWhat is the difference between tesamorelin and CJC-1295 plus ipamorelin for visceral fat?

Tesamorelin and CJC-1295 plus ipamorelin both sit in the growth-hormone signaling lane, but the buying decision starts with the outcome you want to study.\n\nTesamorelin has the clearer visceral-fat evidence. In controlled studies involving people with HIV-associated abdominal fat accumulation, CT-measured visceral adipose tissue fell by roughly 15% to 18% after 26 weeks. That is a specific result in a specific population, but it gives tesamorelin a much stronger evidence anchor for visceral fat than the common retail claims around CJC-1295 plus ipamorelin.\n\nCJC-1295 plus ipamorelin is better understood as a broader GH-support research combination. CJC-1295 acts as a GHRH analog, while ipamorelin activates the ghrelin receptor. Together they are marketed around pulsatile GH release, recovery, sleep, body composition, and lean mass, but those retail outcome claims do not have the same direct controlled evidence as tesamorelin has for CT-measured visceral fat.\n\nBefore buying, compare four things:\n\n1. Confirm the exact identity. CJC-1295 with DAC and CJC-1295 without DAC are materially different products.\n2. Require a lot-matched COA from a named independent lab, with identity and purity data.\n3. Compare effective price per mg after discounts, shipping, and blend math.\n4. For a blend, make sure the COA quantifies both active ingredients rather than reporting one combined purity number.\n\nStart with our full comparison at https://www.peptidepub.com/blog/cjc-1295-ipamorelin-vs-tesamorelin-buyer-guide, check current tesamorelin pricing at https://www.peptidepub.com/prices/tesamorelin, and compare vendor testing transparency at https://www.peptidepub.com/vendors.